Connect with us

Media & Technology

Comeback Time for CytoDyn Inc (OTCMKTS:CYDY) NP Talks BLA for the USA, UK and Canada

Published

on

CytoDyn Inc (OTCMKTS:CYDY) is making an explosive move up the charts since a brief dip below $1.70 per share. New coronavirus cases have been spiking in the US and globally proving the virus is here to stay and won’t be disappearing anytime soon. At the same time results and data coming back from the Pfizer vaccine and Lilly Mab are looking less and less promising the more we learn. This has created a perfect storm for promising biotechs such as Cytodyn who is developing real solutions for the coronavirus pandemic.

CYDY is easily the most exciting stock in small caps that is currently in beast mode after the Company completed a second non-dilutive $28.5 million convertible note financing with conversation rate at $10 per share to expedite licensing applications here and abroad and successful covid-19 trials. CYDY skyrocketed to $10.01 per share earlier this year from a start point of pennies as its wunderdrug leronlimab has continuesd to demonstrate significant potential to attack a number of diseases including cancer, HIV and especially coronavirus. CYDY has attracted a significant short position in recent months which could create another parabolic storm as Cytody once again rises up. Microcapdaily has been reporting on CytoDyn since the stock was trading for pennies.

CytoDyn Inc (OTCMKTS:CYDY) operating out of its executve offices at 1111 Main Street, Suite 660, Vancouver, Washington, is a late-stage biotechnology company focused on the clinical development and potential commercialization of leronlimab (PRO 140), a CCR5 antagonist that continues to demonstrate significant potential to attack a number of diseases including cancer, HIV and coronavirus (COVID-19). CytoDyn believes in the future of precision medicine, more specificity, less side effects. The Company’s target, the CCR5 receptor, has been implicated in multiple disease processes from HIV, GVHD, NASH, stroke recovery, multiple sclerosis, Parkinson’s disease, to metastatic cancer and covid-19. Leronlimab, a CCR5 antagonist, is a once a week, subcutaneous injection. One molecule with multiple opportunities. With precision comes the opportunity for improved safety, convenience, and enhanced efficacy for the patient.

Cytodyn has received conditional acceptance by the FDA of the proprietary name Vyrologix for leronlimab as a combination therapy for highly treatment experienced HIV patients in the United States. In addition, the Company has also received a notice of allowance from the U.S. Trademark Office for the trademark “Vyrologix”.  Leronlimab has completed nine clinical trials in over 800 people and met its primary endpoints in a pivotal Phase 3 trial (leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients). CytoDyn has completed its Phase 2 clinical trial (CD10) for COVID-19, a randomized clinical trial for mild-to-moderate patients in the U.S. and submitted the trial’s Top-line Report to the U.S. FDA for emergency use approval and to the U.K. MHRA to request Fast Track Approval. While enrollment continues in its Phase 3 randomized clinical trial for the severe-to-critically ill COVID-19 population in several hospitals throughout the U.S., an interim analysis on the first 195 patients will be performed in approximately four weeks with results anticipated in mid-October.

To Find out the inside Scoop on CYDY Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

CYDY

In October Cytodyn reported the (MHRA) in the UK has cleared CytoDyn to file its Biologics License Application (BLA) for leronlimab as a combination therapy for multi-drug resistance HIV patients in the U.K. The MHRA’s clearance for the BLA filing included a treatment regimen of one injection per week of 350 mg of the Company’s product leronlimab, as contrasted to the dosage used in the Phase 3 clinical trial conducted in the U.S. for this indication of two consecutive injections of 175 mg per week. During a recent 2-hour meeting between the CytoDyn BLA team and the MHRA, the parties discussed in detail the primary components of the BLA filing: non-clinical, clinical and manufacturing. In connection with the manufacturing section, the Company confirmed it had the necessary one-year of stability data for a 350 mg dose of leronlimab for patients in need of this treatment.

In another huge vote of confidence in Leronlimab, Cytodyn just completed a second non-dilutive $28.5 million convertible note financing with conversation rate at $10 per share without warrants to expedite licensing applications here and abroad and successful covid-19 trials.

Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, stated, “We are very pleased with the institution’s demonstration of confidence and their understanding of leronlimab’s positioning on its regulatory trajectory. This infusion of capital will enable us to accelerate efforts to file BLAs in Canada and the U.K. for leronlimab as a combination therapy for HIV patients with one dose (one 350 mg subcutaneous injection) per week. We continue to expedite enrollment in CD12 (currently at 260 patients), in addition to now accelerating a COVID-19 trial for long-hauler patients, who have no alternative therapy and are rapidly emerging as a widespread health concern. We are well-positioned to supply $2 billion worth of leronlimab to treat COVID-19, if emergency use authorization is approved in the next 2-4 months based on anticipated successful CD12 results.”

https://twitter.com/miaSABS/status/1326514573948620801

For more on CytoDyn Subscribe Right Now!

CYDY is heating up and running northbound with power after the Company completed a second non-dilutive $28.5 million convertible note financing with conversation rate at $10 per share to expedite licensing applications here and abroad and successful covid-19 trials. CytoDyn is among the first biotechs to have a drug that is showing to be effective in the global fight against coronavirus. Leronlimab has shown outstanding results in patients having respiratory complications from COVID-19 providing therapeutic benefit by enhancing the immune response while mitigating the “cytokine storm” that leads to morbidity and mortality in these patients.  CytoDyn recently completed its Phase 2 clinical trial (CD10) for COVID-19, a randomized clinical trial for mild-to-moderate patients in the U.S. While enrollment continues in its Phase 3 randomized clinical trial for the severe-to-critically ill COVID-19 population in several hospitals throughout the U.S., Cytodyn has also been making some big moves lately including getting BLA expert Mahboob U. Rahman, M.D., Ph.D., FACR, on board as Chief Scientific Officer. CYtodyn CEO CEO Nader Pourhassa stated today on the $28.5 million financing: “With this money we now have the financing in place where this can be the last financing we ever need if we get emergency use authorization quickly, if not we can do another one of these $25 million dollar financings and we believe we are there. We are filing BLA for the USA, UK and Canada and we have multiple chance at covid-19 so this raise could be the very last.” We have been reporting on CYDY since the stock was twenty five cents. We will be updating on CYDY when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with CYDY.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in CYDY either long or short and we have not been compensated for this article.

Featured

Creatd, Inc. (OTCMKTS: CRTD) Stock Price Continues to Deteriorate as the Legal Battle with The Lind Partners, LLC Continues

Published

on

Creatd, Inc. (OTCMKTS: CRTD) share value continues to drop after a brief recovery in mid-March. The firm’s stock is still not at the lowest point it has ever been, but it is not too far off at this point. The lowest that the shares have gone was $0.0457, which is the point they reached on October 11th, 2022. After that, in the final months of the previous year, the stock price shot up, reaching $1.6941 per share on November 18th.

The last time when the shares reached this height was in February 2022. However, back then, the price was rapidly spiraling down from a much higher point. Unfortunately for the company and its investors, after reaching $1.6941 in November, the share price crashed in a sharp correction, sinking to $0.50 by the end of November.

CRTD found a strong support at this level, which allowed it to bounce back up to $0.90, which is where the company encountered a strong resistance. It kept bouncing back and forth between these two levels throughout December 2022 and January 2023. However, as time passed, the fluctuations were becoming smaller, as the price seemingly started achieving greater stability. Looking back now, however, it becomes clear that the volatility may have decreased, but the overall trend became bearish somewhere in mid-January.

To Find out the inside Scoop on CRTD, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

CRTD price was dropping again, and in the second half of February, it broke the support level at $0.50, sinking to $0.16 by February 27th. After briefly recovering in early March, the price went back up to $0.3, encountering a resistance here, as well, which pushed it back down to $0.1156 this time, which was on March 14th. In the last 48 hours, the price managed to recover a bit once more, sitting at $0.15 at the time of writing.

Creatd, Inc. (OTCMKTS CRTD) stock price continues to deteriorate as the legal battle with The Lind Partners, LLC continues

Creatd, Inc. (OTCMKTS: CRTD) stock has seen a rough performance over the last year, with only a brief period of recovery in November 2022. Other than that, the last 12 months were marked by nothing but price crashes triggered by various events that followed the company. In recent months — specifically in December — the company announced an upcoming merge with Global Tech Industries, albeit without disclosing the terms of the deal. After that, reports said that Global Tech Industries had decided to bid $100 million in stock in order to acquire Creatd. Creatd even halted any discussions with other potential acquirers for 30 days as part of the LOI. At the time, its CEO and Chairman, Jeremy Frommer, said:

There are two elements to this merger, fundamental and technical. The opportunity to advance the Creatd business model and scale revenues coupled with the unique technical position we find our two public companies in, is a momentous opportunity. At the time of closing of any proposed transaction, GTII share delivery to Creatd shareholders will only occur in instances of registered ownership with the transfer agent or DTC.

For a time, everything was going well for the company until February 24th, when reports emerged that Creatd had terminated the proposed acquisition discussions with Global Tech. This was what triggered the stock crash, as many were disappointed that the deal did not succeed.

Around that time, the company was also struggling with a potential illegal naked short selling, and it launched CEOBLOC to try and fight it. One positive development at the time was the fact that CRTD became available on Upstream, which marked the third issuer to dual-list their shares on Upstream’s blockchain-powered market.

https://twitter.com/UpstreamXchange/status/1625520006770618368

However, the stock was hit with another blow a week ago when Creatd released an update regarding its legal dispute with The Lind Partners, LLC, and the company’s affiliates. The dispute concerns a convertible promissory note that amounts to $900,000.

For more on CRTD Subscribe Right Now!

According to Lind, Creatd breached certain representations and warranties in regard to the note. Lind demanded immediate repayment of the full amount, but Creatd instead decided to offer a number of alternatives. Lind refused to negotiate and Creatd filed a motion to dismiss. The company’s CEO said:

At this early stage, we are strictly trying to analyze data. There is more than enough evidence that there has been unusual trading in CRTD and it demands further investigation. To that end, we have asked legal counsel to look into filing multiple requests of trading records from market makers in CRTD stock. When and if the Company enters the discovery period in The Lind Partners, LLC case, any trading records related to The Lind Partners, LLC that were done with external broker dealers will also be analyzed.

Creatd, Inc. (OTCMKTS: CRTD) is a holding company that offers new economic opportunities to creators using partnerships and technology. The company’s goal is to empower creators and brands, and it claims that each of its companies shares a common mission — to create technologies and develop partnerships that would allow it to unlock new opportunities useful to entrepreneurs, brands, and creators, allowing them to also grow creatively, sustainably, as well as profitably.

For the moment, it appears that the situation is not the best for the company. It is in the middle of legal proceedings, its merger has failed, and its stock is one bad day away from reaching its all-time low. The chart above shows that CRTD is willing to grow and ready to jump on any opportunity, so the company still has a chance. Any piece of good news would likely send its stock to the path of recovery, which is why it is still worth keeping an eye on future developments. We will be updating on CRTD when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with CRTD.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Sang Hyun Cho from Pixabay

Continue Reading

Featured

Global Developments Holdings, Inc (OTCMKTS: GDVM) Share Starts Recovery After a Second Big Drop in Three Months

Published

on

Global Developments Holdings Inc (OTCMKTS: GDVM) share has steadily risen for the past six and a half months. The company’s performance in 2023 has been remarkable.

Global Developments Holdings Inc (OTCMKTS: GDVM) share has been on a steady rise for the past six and a half months. The company’s performance in 2023 shows that the share was growing, then it saw a sudden surge, only to crash back down. However, the company’s 6M chart clearly indicates that the share has been rising steadily, and both rapid surges followed by sudden crashes — one in November/December 2022 and another in February 2023 — were only brief pumps. The stock’s performance overall still indicates that GDVM is seeing a strong, steady rise, which was not affected by these instances of strong volatility.

The GDVM price was fairly stable for the first eight months of 2022, slightly fluctuating around $0.0040. However, at the end of August 2022, the price started to grow. The growth was steady, healthy, and the price kept going up, almost completely uninterrupted until November 3rd. At the time, it reached $0.0527, but after reaching this level, it saw a slight correction to a support at $0.040. After only about a week at this level, a rapid surge took it all the way up to $0.1109. The surge started around November 16th, and it reached its peak by December 6th.

After that, a rapid correction made the price crash back down to $0.056 later on the same day. After an attempt at recovery, the price dropped again on December 14th, this time sinking to $0.038. From there on, the price managed to return back to its steady growth, which actually lasted until late January 2023. At the time, it reached $0.066, when another surge took place, starting on January 27th.

To Find out the inside Scoop on GDVM, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

In the following month, the price climbed up to $0.1359, reaching this height on February 23rd, which was once again followed by a rapid crash back to $0.0726. What followed was a few weeks of stability, which led the price to finally grow back up again, to $0.0862, on March 9th. This was followed by another mild correction to $0.769, which is where the GDVM price sits right now at the time of writing.

Global Developments Holdings, Inc (OTCMKTS GDVM) Share Starts Recovery After a Second Big Drop in Three Months

Global Developments Holdings, Inc (OTCMKTS: GDVM) price behavior has been quite significant over the last six months. However, it is also worth noting that most of these developments — the beginning of the six-month steady growth, as well as rapid price surges in between — took place when some major developments for the company happened. For example, the price started climbing up in August after reports that it reduced OS by 525 million, with rumors that significant moves are being made behind the scenes. At the time, it was rumored that the company was planning a reverse merger, which is exactly what it was doing, as it was discovered later on.

Following that, reports in November emerged, noting that the reverse merger is heating up, especially as the new CEO was affected by massive share reduction. The merger was with a company VeeMost, and by early December 2022, it achieved its 4th advanced specialization. At the time, reports were also praising GDVM as its stock price continued to skyrocket. The stock has been under heavy accumulation from the moment Mr. Melvin Ejiogu, an executive who also acts as President of VeeMost Technologies, became the controlling shareholder. He said:

$GDVM majority control acquired and all outstanding debt purchased. I also purchased 12% of outstanding shares and returned them to the treasury. No dilution will occur. I’ll be sharing updates soon with everyone on our new journey.

His new dilution policy affected a massive share reduction, as mentioned, and trapped the market makers, who were seriously short. The reverse merger stocks have proven that they can be much more explosive than biotechs, assuming that the incoming company has real value. By mid-February, Global Developments became the highest overall rated company in the Shell Companies industry. It had an overall score of 66 while and an average score of 43. This means that, on average, the stock in this industry tends to score higher than 43% of the stock market. However, according to Ejiogu’s tweet published on February 17th, he was working on getting the shell status removed from GDVM.

Global Developments Holdings, Inc (OTCMKTS: GDVM) is a company that provides expert consulting for businesses. It is a principal investment firm that specializes in acquisitions and early-stage financing of emerging growth companies. It describes its service as fast and reliable, and it can help whether its clients need help with finances, advice on theoretical matters, or assistance with practical tasks.

For more on GDVM Subscribe Right Now!

It has a highly-qualified team that is happy to assist with any needs in both private and commercial spheres. The company is based in Delaware, and it was incorporated on December 9th, 2004, as Autobahn International, Inc. However, in 2016, it rebranded to Global Developments Inc and then once more to Global Developments Holdings, Inc, on September 20th, 2018.

For the time being, the company’s stock is still growing steadily after starting to increase in August of last year. The past price surges, followed by sharp corrections, are fairly normal behavior. Prices tend to surge after beneficial developments, and a sharp rise is always followed by a sharp correction. The positive thing is that the price continues to increase after the correction is over, and the chart above clearly shows that the company continues to thrive under the new leadership. We will be updating on GDVM when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with GDVM.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have no position in GDVM and have not been compensated for this article.

Image by David Mark from Pixabay

Continue Reading

Featured

Asia Broadband, Inc (OTCMKTS: AABB) Stock Price Surges as the Firm Takes a Stance Against Market Maker Manipulation Practices

Published

on

Asia Broadband, Inc. (OTCMKTS: AABB)

Asia Broadband, Inc. (OTCMKTS: AABB) saw its stock price surge by over 10% in the last 24 hours following its decision to pursue market manipulation legal action against some major market makers. The firm’s stock price surged from $0.0290 to the current $0.0334, which was also the closing price on Thursday, March 9th. Before this, the firm’s price has had several spikes up over the last six months, although each of them was too sharp to last, and they were always followed by just as strong corrections. The last big example came around February 21st, with January 31st before that and January 17th before that.

To Find out the inside Scoop on AABB, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

The situation was slightly different in late 2022 when Asia Broadband saw a strong price surge around November 23rd, which led it to the high point of $0.0559 by December 6th. The following correction took the price back down to an average level of $0.033, with the price fluctuating around it until early February 2023. After that, the price sank to the support at $0.030, and it just broke it in the early days of March, going down to $0.028 before surging back up over the last two days.

Over the past six months or so, each of the strong price reactions that AABB has displayed took place roughly around the same time as some important events for the company. For example, in December 2022, the company launched the GoldenBaboons.com website in preparation for the launch of its Gold-Backed NFT Baboons collection, which went live in January. The collection Golden Baboons Mining Club (GBMC) was the first NFT collection that AABB has created and published. Furthermore, it is backed by gold, like the company’s AABBG token.

Another time the price had reacted was in January of this year, right after the reports of Asia Broadband completing a plant site purchase to process gold and silver ore. The firm announced the purchase of the new processing facility, and an evaluation report has estimated the stockpile to represent more than $800 million in gold and silver. Reports at the time have called the stockpile processing project the largest high-yield asset addition for the firm to date, and it was considered a part of its strategic expansion initiative, meant to help the Company acquire gold production and increase AABB’s physical gold holdings. Then, only about a week after that, new reports said that Asia Broadband is continuing its strategic expansion of its Central America cryptocurrency operations hub in El Salvador — specifically, in its Bitcoin City.

Finally, in mid-February, the company announced a registration deadline to purchase its gold-backed Baboons NFT collection during the NFT mint event. The deadline was February 22nd, and the minting took place after that, on February 28th. As for this latest AABB price surge, it came around the time when another new report emerged, stating that Asia Broadband pursues market manipulation legal action against major market makers for AABB shares on OTC Markets.

The legal initiative has actually progressed for months, as the company noted that many shareholders and public firms received expressing that the AABB share price was subjected to long-term repression by deceptive and false trading practices. Furthermore, other OTC Market issuers were already publicly exposed and legally challenged due to their market maker manipulation practices. Apart from that, Asia Broadband is also pursuing legal action against a number of parties for multiple defamatory internet posts.

The Company experienced similar defamation attacks several years ago, and the situation was resolved to the firm’s advantage, with the posts permanently removed. The company’s CEO and AABB President, Chris Torres, said:

We have an obligation to our shareholders to do everything in our power to protect their investments in our Company’s shares. Our share price is not reflecting the true value attributed to the Company’s successes in recent years due to deceitful and profiteering market manipulation.

While the name, Asia Broadband, Inc. (OTCMKTS: AABB), suggests that this is a telecommunications firm, AABB is actually a mining stock. Operating as a resource company with a special focus on the production, supply, and sale of precious and base metals, Asia Broadband primarily sells to Asian markets.

The firm uses specific geographic expertise, coupled with extensive industry contacts and a long and rich experience to facilitate innovative distribution processes from the production and supply of base and precious metals in Mexico to its clients, which can be found all over Asia. With that said, the company’s most prominent move as of late has been an attempt to develop a gold-backed cryptocurrency token and a gold-backed NFT collection mentioned earlier. The token itself is known as AABBG, and it was backed by $30 million in gold holdings as of 2021 when it was originally released.

For more on AABB Subscribe Right Now!

Despite the relatively poor stock price performance, Asia Broadband, Inc (OTCMKTS: AABB) is a mining firm that has great potential for the future. Its involvement with crypto assets and the fact that it supplies Asian clients both work in its favor. Asia is emerging as one of the leading regions in terms of technology and digital assets. With the company operating in the West on behalf of the East, it is in a perfect position to grow. Furthermore, if allegations of defamation and market manipulations from its lawsuit turn out to be true, that would explain the difficulties in AABB’s performance that the company has been facing, which could allow its stock to start growing once these negative aspects get removed. We will be updating on AABB when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with AABB.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in AABB, either long or short, and we have not been compensated for this article

Image by Tom und Nicki Löschner from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.